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Abstract: 
Objectives: To evaluate the performance of five CVD risk scores developed in diabetes 
populations and compare their performance to QRISK2. 
Research Design and Methods: A cohort of people diagnosed with type 2 diabetes between 
2004 and 2013 was identified from the Scottish national diabetes register. CVD events were 
identified using linked hospital and death records. Five-year risk of CVD was estimated using 
each of QRISK2, ADVANCE, Cardiovascular Healthy Study (CHS), New Zealand Diabetes 
Cohort Study (DCS), Fremantle, and the Swedish National Diabetes Register (NDR) risk 
scores. Discrimination and calibration was assessed using Harrell’s C-statistic and calibration 
plots, respectively.  
Results: The external validation cohort consisted of 181,399 people with type 2 diabetes and 
no history of CVD. There were 14,081 incident CVD events within five years follow-up. The 
five-year observed risk of CVD was 9·7% (95% CI: 9·6, 9·9). C-statistics varied between 
0·66 and 0·67 for all risk scores. QRISK2 overestimated risk, classifying 87% to be at high 
risk for developing CVD within five years; ADVANCE underestimated risk and the Swedish 
NDR risk score calibrated well to observed risk.  
Conclusions: None of the risk scores performed well among people with newly diagnosed 
type 2 diabetes. Using these risk scores to predict five-year CVD risk in this population may 
not be appropriate.  
  
  
Introduction:  
Despite improvements through earlier diagnoses and improved treatments,[1] cardiovascular 
disease (CVD) mortality and morbidity risk among people with type 2 diabetes remains 
markedly higher than in people without diabetes[2, 3]. The effect size depends on the sub-type 
of CVD as well as age, sex, diabetes duration, ethnicity and socio-economic status.[4, 5]  
Accurate CVD risk estimation in people with type 2 diabetes without established 
CVD can identify patients at high risk of developing CVD and can thus be used to guide 
appropriate treatment, for example with statins, illustrate to patients the likely effects of 
lifestyle choices and identify eligible participants for clinical trials. The United Kingdom 
(UK) clinical guideline network, the National Institute of Health and Clinical Excellence 
(NICE) recently updated its guidelines to advocate using the QRISK2 score,[6] a risk score 
developed in the general population,[7] to ascertain CVD risk in people with type 2 diabetes. 
Despite this recommendation, the performance of QRISK2 has not been independently, 
externally validated in people with type 2 diabetes.  
Several CVD risk scores have also been developed specifically for use among people 
with type 2 diabetes.[8] While most of the earliest diabetes-specific CVD risk scores, such as 
the United Kingdom Prospective Diabetes Study (UKPDS) risk engine have been extensively 
externally validated, many of the contemporary risk scores have not.[8-10] Though one recent 
study did externally validate several contemporary risk scores,[11] this study was limited by 
small sample sizes of the external validation cohorts resulting in imprecise estimates of 
calibration and discrimination.[12, 13] In addition, few external validation studies have been 
conducted on statin-naïve participants.  
Scotland maintains a national register of all patients with a diagnosis of type 2 
diabetes, and this register can be linked to population-based hospitalisation and mortality 
  
records. Consequently, this data source offers an opportunity to explore the performance of 
existing risk scores in a contemporary population of people with type 2 diabetes. 
We evaluated the predictive performance of five diabetes-specific CVD risk scores in 
an external validation cohort of people with type 2 diabetes in Scotland and compared their 
performance to QRISK2.  
Research Design & Methods:  
Study design and participants:  
Data for these analyses were obtained from the population-wide Scottish Care Information-
Diabetes (SCI-Diabetes) database. This dynamic clinical register was established in 2000 and 
is populated by patient data from primary care and hospital diabetes clinics. Outcome data 
were obtained from linkage to the Scottish Morbidity records (SMR01), a national hospital 
admission dataset, and death registrations. Approval for generation and analysis of the linked 
dataset was obtained from the Caldicott guardians of all Health Boards in Scotland, the 
Privacy Advisory Committee of the Information Services Division of NHS National Services 
Scotland (ISD) and the multi-centre research ethics committee. 
The external validation cohort consisted of people diagnosed with type 2 diabetes 
between 1st January 2004 and 1st June 2016 in Scotland. This time-frame was chosen since 
SCI-Diabetes achieved over 99% completeness of primary and secondary care clinics from 
2004 onwards. The cohort was restricted to people who had no previous history of CVD (as 
defined below) and who were aged between 30 and 89 years at date of diagnosis of diabetes 
due to small numbers of people in other age groups. We excluded people with a history of 
CVD at diagnosis of diabetes from our cohort since all but one of the risk scores we wished 
to validate were designed to estimate risk of incident CVD. We included individuals who 
were prescribed statins prior to and following type 2 diabetes diagnosis in the main analyses 
  
but conducted sensitivity analyses in sub-populations restricted to i) people who had not been 
prescribed statins prior to type 2 diabetes diagnosis ii) people who had not been prescribed 
statins prior to type 2 diabetes diagnosis or during follow-up. 
Members of the cohort were followed up from baseline, defined as date of diabetes 
diagnosis, until date of death, date of first CVD event or study end-date (1st June 2016), 
whichever came first.  
Outcome: 
CVD was defined as any hospital admission or death from myocardial infarction, stroke, 
unstable angina, transient ischaemic attack, peripheral vascular disease and coronary, carotid, 
or major amputation procedures between baseline and 1st June 2016. International 
Classification of Disease, version 10 codes and Office of Population Censuses and 
Surveys Classification of Interventions and Procedures version 4 codes used for identifying 
CVD may be found in the supplementary material.  
Selected risk scores: 
QRISK2 was developed using data from the QRESEARCH database, is based upon a Cox 
proportional hazard model and predicts 10-year risk of CVD.[7] A previous systematic review 
identified twelve CVD risk prediction models designed for use among individuals with type 2 
diabetes.[9] Of these, five (the Swedish national diabetes register risk score (NDR) [14], the 
Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation 
(ADVANCE) CVD risk score,[15] the Fremantle risk score,[16] the New Zealand Diabetes 
Cohort study risk score (NZ DCS),[17] and the Cardiovascular Health Study (CHS) risk 
score[18] were chosen as these were developed to predict CVD while the remaining risk scores 
predict only coronary heart disease or stroke. Since the publication of the systematic review, 
an additional risk score, the Atherosclerosis Risk in Communities (ARIC) risk score for CVD 
has been developed.[19] However, this risk score includes several predictors (alcohol 
  
consumption, physical activity) which are not available in SCI-Diabetes and linked data 
sources and so was not considered in this validation exercise.  
The characteristics of QRISK2 and the five diabetes-specific risk scores are presented in 
Table 1. All five diabetes-specific risk scores were derived from Cox proportional hazards 
models; three predict five-year risk, while CHS predicts 10-year risk and ADVANCE 
predicts four-year risk. The five-year baseline hazard for QRISK2 has been published while 
the five-year baseline hazards were obtained from the study investigators for CHS and were 
estimated by extrapolation for ADVANCE.  
Predictors used in risk models:  
Taken together, the selected CVD risk prediction models contain the following predictors: 
age, sex, diabetes status (type 1/type 2/no diabetes), diabetes duration, ethnicity, Townsend 
deprivation score, systolic blood pressure, pulse pressure, smoking status, body mass index, 
total:HDL-cholesterol ratio, HDL-cholesterol, non-HDL cholesterol, glycated haemoglobin, 
glucose-lowering medications, micro/macro albuminuria, albumin-creatinine ratio, creatinine, 
family history of CVD, anti-hypertensive medications, lipid-lowering medications, 
retinopathy, chronic kidney disease, rheumatoid arthritis and atrial fibrillation.  
Definitions of predictors in external validation cohort 
Baseline predictor values were defined as measurements recorded closest to baseline, no 
more than 24 months prior to or 12 months after date of diagnosis of diabetes. Any predictor 
without a measurement within this timeframe was declared missing. Prescriptions of anti-
hypertensive and lipid-lowering medications occurring within the three months preceding 
baseline date were defined using British National Formulary (BNF) codes 2·5 and 2·12, 
respectively. Chronic kidney disease was defined as a recording of estimated glomerular 
  
filtration rate of <60ml/min/1·73m2 and/or a hospital admission for chronic kidney disease 
(ICD-10 codes: N18, I12-13, ICD-9 codes: 585).  
Some predictors were not available, or had different definitions compared to the five scores 
within SCI-Diabetes and linked datasets and, therefore, some proxy predictors were used. 
Presence of rheumatoid arthritis was defined as patients with any prescription for disease 
modifying anti-rheumatic drugs, defined with a BNF code of 10·1·3 prior to baseline. Atrial 
fibrillation was defined as a hospital admission record, including diagnosis codes for atrial 
fibrillation (ICD10: I48, ICD9: 427·3) or a warfarin prescription in the absence of a hospital 
record of prior deep vein thrombosis or pulmonary embolism.[20] For area-based deprivation, 
the contemporary Scottish measure (Scottish index of multiple deprivation, (SIMD))[21] was 
mapped across to the historical Townsend score (see Supplementary table 1). Family history 
was estimated as the conditional probability of having a family history of CVD based on age 
and deprivation status (SIMD) using data from the 2014 Scottish Health Survey (see 
Supplementary table 2).[22]  
We conducted sensitivity analyses whereby all proxy categorical predictors (atrial fibrillation, 
rheumatoid arthritis, family history of CVD) were set to null and where the Townsend score 
was set to the mean. Further sensitivity analyses were conducted to include prevalent diabetes 
whereby baseline was defined as the latest of 01-01-2010, date of diabetes diagnosis or date 
of 30th birthday. Lastly, we examined whether the predictive performance of the selected risk 
scores changed over time (based on diabetes diagnosis before or during/after 2011). 
Statistical analyses:  
Missing predictor data were imputed using multiple imputation assuming data were missing 
at random (mice package in R)[23]. The imputation model included all predictors and the 
outcome (follow-up time and CVD event) and was used to generate 20 imputed datasets. 
  
Estimates were pooled using Marshall’s adaption of Rubin’s rules.[24] Complete case analyses 
were also conducted as additional sensitivity analyses.  
Observed five-year risk of CVD was estimated using the Kaplan-Meier estimator. Five-year 
risk of CVD was estimated at time of type 2 diabetes diagnosis using the five selected CVD 
risk scores and QRISK2. The predictive performance of the selected risk scores was assessed 
by examining measures of calibration and discrimination. Calibration describes how closely 
the predicted five-year risk and the observed five-year risk agree and was assessed by plotting 
smoothed observed incidence by predicted incidence using Kaplan-Meier estimates.[25] 
Calibration-in-the-large statistics and calibration slopes for which values of 0 and 1, 
respectively, indicate good calibration were also calculated. Calibration-in-the-large statistics 
compare the mean predicted risk and mean observed risks. Calibration statistics were also 
calculated for the recalibrated risk scores following adjustment of the baseline hazard to that 
of the external validation cohort.[26, 27] Discrimination describes the model’s ability to 
differentiate between patients who developed CVD to those that did not and was assessed 
here by calculating Harrell’s C-statistic. This statistic describes the probability that, for any 
pair of individuals among whom one developed CVD and the other did not develop CVD, the 
predicted risk of the outcome is higher for the individual who did subsequently develop the 
disease.[28] A C-statistic of 1 denotes perfect discrimination and a value of 0.5 denotes a 
prediction model that performs no better than a flip of a coin.  
We calculated the number of people classified as high risk, based on the cut-off point in 
national clinical guidelines (≥10% estimated risk in QRISK2) or low risk (<10% estimated 
risk in QRISK2).[6] 
All statistical analyses were carried out in R version 3·2·2 (2015-08-14).  Calibration plots 
were generated using the rms package in R.[29] The reporting of this external validation study 
  
is in accordance with the Transparent Reporting of a multivariable prediction model for 
individual Prognosis or diagnosis (TRIPOD) guidelines.[30] 
  
Results 
There were 218,607 individuals diagnosed with type 2 diabetes in Scotland between January 
2004 and June 2016 (Table 2). Of these, 37,208 had a previous history of cardiovascular 
disease and were excluded from the analyses, leaving 181,399 individuals to form the 
external validation cohort. Of the 26 predictors included in the risk models, 11 had missing 
values and the average missingness was 18%. There were a total of 118,098 individuals with 
incomplete predictor data, including 33,210 individuals with a single incomplete predictor 
and a further 42,834 individuals with two incomplete variables only (Supplementary Table 
3). 
Overall, there were 14,081 incident CVD events during 673,740 person-years of follow-up 
and the five-year observed Kaplan-Meier risk of CVD was 9·7% (95% CI: 9·6, 9·9). The 
median follow-up time was 5 years and there were 91,549 individuals who were followed-up 
for at least five years. There were 10,023 non-CVD deaths during follow-up.  
Within the external validation cohort, 36,471 individuals had been prescribed statins prior to 
date of diabetes diagnosis. During follow-up, 71,585 individuals were prescribed statins and 
the median time until statin initiation was 141 days. 
Calibration & Discrimination 
  
Measures of calibration and discrimination are presented in Table 3 and calibration plots are 
presented in Figure 1. Briefly, the agreement between observed and predicted risks 
(calibration-in the-large) was better using the Swedish NDR, CHS and NZ DCS risk scores 
than for the QRISK2 and ADVANCE risk scores. Overall, QRISK2 overestimated risk while 
ADVANCE underestimated risk across all risk groups. C-statistics for each of the models 
ranged between 0.663 (0.658, 0.668) and 0.674 (0.669, 0.679) for the whole population. 
These values decreased following stratification by age, particularly in older age groups. 
Supplementary Figure 1 presents the distribution of predicted risks for each risk score. 
Risk Classification 
With a 10% threshold for high risk of developing CVD, QRISK2 classified 86·8% of the 
cohort as high risk, capturing 13,633 (96·8%) of the subsequent CVD events. In comparison, 
3·2%, 58·8%, 25·8%, 82·6% and 37·3% of the cohort were classified as high risk, capturing 
8·4%, 80·8%, 59·2%, 94·7% and 46% of the CVD events using the ADVANCE, CHS, 
Fremantle, NZ DCS and Swedish NDR risk scores, respectively (Supplementary Table 4)  
Sensitivity Analyses  
After recalibration of the risk scores, calibration improved slightly for the ADVANCE risk 
score (Supplementary Figure 2). The agreement between observed and predicted risks 
estimated by QRISK2 deteriorated further. The median predicted risk estimated by the 
recalibrated QRISK2, ADVANCE, CHS, Fremantle Diabetes Study, NZ DCS and the 
Swedish NDR risk scores were 94·7%, 2·5%, 4·7%, 4·1%, 6·5% and 6·4%. 
 
  
Among the subset of individuals who were not prescribed statins prior to diabetes diagnosis 
(n=144,928), there were 9,572 events during 533,006 person-years of follow-up. Measures of 
calibration and discrimination for this subset yielded similar results to the main analyses 
(Supplementary Figure 3 and Supplementary Table 5). These findings were also replicated in 
the subset of individuals who were not prescribed statins prior to diabetes diagnosis or during 
follow-up (Supplementary Figure 4, Supplementary Table 5), when proxy variables were 
replaced with null or mean values (Supplementary Figure 5, Supplementary Table 5), when 
people with prevalent diabetes were included in the cohort (Supplementary Figure 6, 
Supplementary Table 6) and when complete case analyses were used omitting missing data 
(Supplementary Figure 7, Supplementary Table 5). The predictive performance of each of the 
risk scores varied only slightly depending on year of diabetes diagnosis (<2011 vs. ≥2011) 
(Supplementary Table 5).   
Conclusions:  
Using a population-wide diabetes dataset, we have conducted the largest external validation 
of several contemporary CVD risk scores among people with type 2 diabetes to date and 
conducted the first external evaluation of QRISK2, the recommended CVD risk score for 
people with type 2 diabetes in England and Wales.  
The ability of the assessed risk scores to discriminate between people who did and did not 
develop incident CVD as assessed by Harrell’s C-statistics was similar with all C-statistics 
for all risk scores below 0·68. The median predicted risk using QRISK2 was 23·5% 
compared to an observed risk of 9·3% and QRISK2 classified over 86% of people with type 2 
diabetes as high risk. Compared to QRISK2, the agreement between predicted and observed 
risks using the risk scores developed in diabetes populations were generally better. For 
example, the median predicted risk using the CHS and Swedish NDR risk scores was 11·7% 
and 8·3%, respectively. The ADVANCE risk score exhibited the poorest calibration and 
  
severely underestimated risk of CVD in people with type 2 diabetes in Scotland. 
Recalibration by adjustment of the baseline hazard worsened the performance of QRISK2 
since the five-year baseline hazard of the external validation study was higher than the 5-year 
baseline hazard in the QRESEARCH development dataset. More advanced recalibration 
approaches in which regression coefficients of the predictors are adjusted, are required to 
ensure better agreement between QRISK2 predicted and observed risks in people with type 2 
diabetes in Scotland.[6] The poor performance of QRISK2 among people with type 2 diabetes 
could lead to the over-treatment of low risk people. 
Findings from other studies: 
Although UK national clinical guidelines recommend the use of QRISK2 to estimate CVD 
risk in people with type 2 diabetes, the performance of QRISK2 in estimating CVD risk in 
external populations has not previously been assessed. However, an evaluation of the 
performance of QRISK2 in people with type 2 diabetes has been made using a subset of 
people with type 2 diabetes in the QRESEARCH database and is described in an online 
report.[31] This approach to validation, whereby the performance of the model was assessed in 
a subset of the derivation cohort is likely to have led to optimistic measures of performance. 
As expected therefore, the C-statistics describing the discriminative ability of QRISK2 were 
better in this evaluation than in our validation (C-statistics: 0·703 [0·691, 0·715] in women 
and 0·696 [0·685, 0·706] in men) while the agreement between predicted and observed risks 
was also better.  
Most previous studies have reported that CVD risk scores developed in general populations 
underestimate risk in people with type 2 diabetes,[8] so we were surprised to find that 
QRISK2 overestimated risk in our external validation cohort. However, this difference may 
be partly explained by the inclusion of prevalent type 2 diabetes patients in the QRISK2 
  
derivation cohort, though sensitivity analyses in which people with prevalent type 2 diabetes 
were included in the external validation cohort did not markedly improve QRISK2’s 
performance (Supplementary Figure 6). Including diabetes in the risk score as a categorical 
variable and in an interaction with age as in this risk score and others is unlikely to 
sufficiently capture the complex relationship between diabetes and CVD, particularly the 
effect of diabetes duration on CVD risk. Similarly, predicting CVD risk in people type 2 
diabetes is likely to be further complicated by the possible presence of type 2 diabetes 
subtypes with distinct disease trajectories.[32] Identifying whether the incorporation of 
variables denoting type 2 diabetes subtypes within existing risk scores would improve their 
performance would be of interest for future research. 
Previous validation studies of contemporary diabetes-specific risk scores are limited. One 
recent external validation study assessed the performance of the five diabetes-specific risk 
scores in three separate cohorts; the European Prospective Investigation into Cancer and 
Nutrition (EPIC)-NL, EPIC-Potsdam and the Secondary Manifestations of ARTerial disease 
(SMART) study.[33] Expected to observed ratios varied between 1·06 (0·81, 1·40) and 1·46 
(1·04, 2·05). The risk scores exhibited poor discriminative ability in the three external 
validation cohorts with C-statistics ranging from 0·54 (0·46, 0·63) for the CHS risk score in 
EPIC-NL to 0·69 (0·59, 0·79) for the Fremantle risk score in SMART. Within each external 
validation cohort, the discriminative ability was similar for each risk score, a finding 
replicated in the present study and a possible reflection of the limitations of Harrell’s C-
statistic in the presence of extensive censoring.[28] Unfortunately, the wide confidence 
intervals owing to the small numbers of events in each external validation cohort (52 events 
in EPIC-NL, 73 in EPIC-Potsdam and 58 in SMART) made interpretation of the performance 
of these models difficult and prevented the authors identifying the strongest performing risk 
score. The ADVANCE risk score was externally validated in 1,836 patients enrolled in the 
  
DIABHYCAR clinical trial and exhibited similar discrimination (C-statistic: 0·69 [0·65, 
0·72]) as reported here, but it underestimated risk in the DIABHYCAR population.[15]  
Beyond differences in the performance of different health systems, there are likely to be a 
number of explanations for the overall poor performance of the assessed risk scores.[34] One 
major potential explanation is differences in the distribution of outcomes and predictors (i.e. 
the case mix) in the external validation cohort compared to the derivation cohorts. Different 
age distributions are likely to be the most important difference between development and this 
external validation cohort, as indicated by the age-stratified measures of discrimination and 
calibration in Table 3. A further factor which may have contributed to poor performance in 
this cohort are different eligibility criteria. For example, ADVANCE was a trial with strict 
inclusion criteria that made for a very non-standard population.[35] Definitions of CVD also 
varied between derivation and validation cohorts. While QRISK2 identifies angina through 
general practice records, the present study only includes hospital admissions for angina and 
therefore angina incidence will be underestimated. Other factors which may have contributed 
to the poor performance of these risk scores was the use of proxies, different time frames of 
the outcome (10-year development vs. 5-year validation) and potentially differences in 
patterns of glucose-lowering therapies that may have different effects on CVD risks.   
Strengths/Weaknesses: 
This study had a number of strengths. By utilising population-based registers we were able to 
assemble the largest external validation cohort of people with type 2 diabetes to assess and 
directly compare the performance of several CVD risk scores to date. The large cohort also 
enabled the assessment of each model’s performance in subsets of people based upon statin 
exposure. The population-based nature of these data also ensured low risk of selection biases 
influencing our findings and enabled us to present results which are applicable to the entire 
population of Scotland.  
  
A number of weaknesses of the study should be acknowledged. Firstly, the use of proxy 
measures for some of the predictor variables may have contributed to the poor performance 
of the models for which these were required. However, by conducting sensitivity analyses to 
explore the likely effect of using these proxy measures, we have shown that this limitation is 
unlikely to have had a large effect on the overall findings of our study. Concerns surrounding 
the accuracy of the recording of CVD events may be a further limitation of this work. 
Nonetheless, findings from the West of Scotland Coronary Prevention Study 
(WOSCOPS) indicated that linkage to hospital admissions registers for acquiring CVD 
events may be as effective as direct patient contact.[36] Finally, we were unable to validate all 
existing risk scores for people with type 2 diabetes due to the unavailability of some 
predictors, though risk scores which include variables that are generally not measured may be 
difficult to implement in clinical practice. We acknowledge that further research is needed to 
establish whether diabetes treatment contributes to CVD risk independently of other factors. 
Such research will be particularly valuable for new diabetes drugs that appear to have a 
beneficial effect on CVD in trial populations. 
Implications/Conclusions: 
Risk scores have important roles in guiding treatment, communicating risks to patients and 
for identifying eligible clinical trial participants. Unfortunately, we have shown that many 
existing risk scores do not accurately predict incident CVD risk in people with newly 
diagnosed type 2 diabetes, though risk scores developed in diabetes populations generally 
performed better than QRISK2. Current guidelines which recommend using QRISK2 would 
classify 87% of people with type 2 diabetes in Scotland as high risk leading to the potential 
over-treatment of low risk individuals. This approach is therefore not dissimilar to classifying 
all people aged over 40 years and with type 2 diabetes as high risk, as recommended in 
several existing clinical guidelines.[37-39] 
  
We conclude that there is scope to improve risk scores for incident CVD among people with 
type 2 diabetes and suggest that QRISK2 and the five diabetes-specific risk scores, without 
recalibration, do not currently meet the standard for application to real-world patients in 
Scotland.  
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Tables  
Table 1. Characteristics of QRISK2 and five CVD risk scores for use in people with type 2 diabetes 
Name Population Cohort Type Time-frame Follow-
up time, 
years 
Main Outcome Risk Factors Internal 
validation C 
statistic:  
  
QRISK2 risk 
score 
2.3 million 
people aged 
35-74 years 
in England 
and Wales 
without 
previous 
CVD 
Electronic 
health 
records 
1993 to 
2008 
Mean: 
7.3 for 
women. 
6.9 for 
men 
10-year risk of CHD, 
stroke or transient 
ischaemic attack 
(ICD-10: I20, I22-I25, 
I63-I64). Not 
peripheral arterial 
disease.  
Age, sex, diabetes status, ethnicity, 
BMI, total:HDL cholesterol, systolic 
blood pressure, atrial fibrillation, 
smoking, treated-hypertension, 
Townsend social deprivation score, 
Rheumatoid arthritis, family history of 
CHD. 
Men: 0.792 
(0.789, 
0.794) 
Women: 
0.817 
(0.814, 
0.820) 
  
Swedish 
National 
Diabetes 
register risk 
score[14] 
24,288 
people aged 
30-74 years 
in Sweden 
Register 2002 to 
2007 
Mean: 
4.8 
5-year risk of fatal or 
non-fatal CVD. Non-
fatal CHD (ICD10: 
I20-I21) PCI or 
CABG, fatal CHD 
(I20-I25), or non-fatal 
or fatal stroke (I61, 
I63, I64). 
Age, sex, diabetes duration, BMI, 
total:HDL cholesterol, SBP, HbA1c, 
smoking, treated hypertension, lipid-
lowering drugs, Micro & macro-
albuminuria, previous history of CVD  
0.72 
ADVANCE 
CVD risk score 
[15]  
7,168 
people aged 
≥55 years 
without 
previous 
CVD from 
215 
collaborating 
centers in 
20 countries 
Trial Recruitment: 
2001 to 
2003 
Mean: 
4.5  
4-year risk of fatal or 
non-fatal MI or stroke 
or cardiovascular 
death. ICD-9 codes 
for non-fatal event: 
430-435, 437-438, 
410. ICD-9 codes for 
fatal event: 394-459, 
798.9. 
Age, sex, diabetes duration, HbA1c, 
atrial fibrillation, treated hypertension, 
albumin-creatinine ratio, pulse 
pressure, retinopathy, Non-HDL 
cholesterol 
0.70 (0.68, 
0.73) 
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Name Population Cohort Type Time-frame Follow-
up time, 
years 
Main Outcome Risk Factors Internal 
validation C 
statistic:  
from Asia, 
Australia, 
Europe, and 
North 
America. 
Fremantle 
Diabetes 
Study risk 
score [16] 
1,240 
people with 
a mean age 
of 64.1 
years from 
Fremantle, 
Western 
Australia 
Observational 
cohort study 
Recruitment: 
1993 to 
1996. 
Follow-up 
until 2006 
Mean: 
4.5 
5-year risk of fatal or 
non-fatal MI, stroke 
or sudden death (No 
ICD codes provided)  
Age, sex, ethnicity, prior CVD, 
Glycated haemoglobin, Albumin-
creatinine ratio, HDL-cholesterol,  
0.80 
The New 
Zealand 
Diabetes 
Cohort Study 
(NZ DCS) risk 
score [17] 
36,127 
people with 
a median 
age of 59 
years and 
without 
previous 
CVD from 
New 
Zealand 
Observational 
cohort study 
2000 - 2009  Median: 
3.9 
First fatal or non-fatal 
CVD event, and 
coronary and 
peripheral arterial 
procedures (See: 
link)  
Age, sex, diabetes duration, ethnicity, 
total:HDL cholesterol, systolic blood 
pressure, Glycated haemoglobin, 
smoking, albuminuria 
0.68  
Cardiovascular 
Health Study 
risk score[18] 
782 men 
people aged 
over 65 and 
without 
previous 
CVD from 
four field 
centres in 
the United 
States 
Observational 
cohort study 
Recruitment 
between 
1989 and 
1993. 
Follow-up 
until 1999 
Mean: 7 10-year risk of MI, 
stroke and death (No 
ICD codes provided) 
Age, sex, smoking status, HbA1c, 
systolic blood pressure, total 
cholesterol, HDL-cholesterol, 
creatinine, use of glucose-lowering 
medications 
0.64 
CHD: Coronary Heart Disease, BMI: Body mass index, HDL-cholesterol: High density lipoprotein cholesterol, PCI: Percutaneous coronary intervention, CABG: Coronary 
Artery Bypass Grafting, SBP: Systolic blood pressure, HbA1c: Glycated haemoglobin, MI: Myocardial infarction. 
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Table 2. Baseline characteristics of individuals diagnosed with type 2 diabetes in Scotland 
between 2004 and 2016 by subsequent five-year CVD outcome status over a median follow-
up of 4.9 years 
Characteristic  CVD event 
No CVD 
event 
N  14,081 167,318 
Median age at diagnosis, yrs (IQR)  66.5 (17.4) 59.3 (18) 
Sex (%) 
Men 8,292 (8.4) 90,604 (91.6) 
Women 5,789 (7) 76,714 (93) 
Ethnicity 
White 9,808 (7.6) 118,633 (92.4) 
SE-Asian 220 (5.4) 3,836 (94.6) 
Other 480 (6) 7,579 (94) 
SIMD (%) 
Most Deprived 3,700 (8.4) 40,349 (91.6) 
2 3,361 (8.2) 37,867 (91.8) 
3 2,780 (7.6) 33,569 (92.4) 
4 2,463 (7.5) 30,576 (92.5) 
Least Deprived 1,777 (6.6) 24,957 (93.4) 
Mean systolic blood pressure, mmHg (SD)  139.9 (19.9) 138.6 (17.7) 
Mean pulse pressure, mmHg (SD)  60.4 (16.3) 57 (14.7) 
Smoking status (%) 
Current smoker 3,854 (9.7) 35,946 (90.3) 
Ex-smoker 5,463 (8.9) 56,232 (91.1) 
Never smoker 4,699 (5.9) 74,493 (94.1) 
Mean BMI, kg/m (SD)  31.3 (6.5) 32.9 (6.9) 
Mean total:HDL cholesterol ratio (SD)  4.5 (1.6) 4.7 (1.6) 
Non-HDL cholesterol ratio, mmol/mol (SD)  3.9 (1.3) 4.1 (1.3) 
Mean glycated haemoglobin, mmol/L (SD)  64 (23) 64.8 (23.4) 
Mean glycated haemoglobin, % (SD)  8.0 (4.1) 8.1 (4.2) 
Albuminuria (%) 
Normal 5,664 (6.6) 80,735 (93.4) 
Micro 1,466 (9.3) 14,333 (90.7) 
Macro 215 (13.6) 1,361 (86.4) 
Albumin-creatinine ratio (SD)  5.3 (18.2) 3.3 (12.4) 
Prescribed anti-hypertensive medications 
(%) 
Yes 6,053 (9.3) 58,958 (90.7) 
No 8,028 (6.9) 108,360 (93.1) 
Prescribed rheumatoid arthritis 
medications (%) 
Yes 210 (9.7) 1,946 (90.3) 
No 13,871 (7.7) 165,372 (92.3) 
Atrial Fibrillation (%) 
Yes 1,487 (17.3) 7,098 (82.7) 
No 12,594 (7.3) 160,220 (92.7) 
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Retinopathy (%) 
Yes 1,735 (9.2) 17,068 (90.8) 
No 12,346 (7.6) 150,250 (92.4) 
Chronic Kidney Disease (%) 
Yes 3,547 (13.6) 22,454 (86.4) 
No 9,712 (6.7) 135,537 (93.3) 
Prescribed statins prior to diabetes 
diagnosis (%) 
Yes 4,509 (12.4) 31,962 (87.6) 
No 9,572 (6.6) 135,356 (93.4) 
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Table 3. Age-stratified calibration and discrimination statistics for QRISK2 and five 
diabetes-specific risk scores  
Risk 
score 
Age 
group 
Observed 
5-year 
risk 
Median 
predicted 
5-year 
risk, % 
(IQR) 
Calibration-
in-the-large 
Calibration 
slope 
C-statistic 
(Discrimination) 
QRISK2 Overall 9.7 24.07 
(21.21) 
-0.14 0.376 (0.376 
,0.377) 
0.674 (0.669, 
0.679) 
30-45 3.4 8.73 (9.71) -0.06 0.208 (0.208 
,0.208) 
0.666 (0.644, 
0.689) 
46-60 6.8 18.26 
(13.81) 
-0.11 0.272 (0.272 
,0.273) 
0.632 (0.623, 
0.641) 
61-75 11.5 29.51 
(16.54) 
-0.19 0.317 (0.317 
,0.317) 
0.604 (0.597, 
0.612) 
>75 21.0 45.01 
(17.55) 
-0.24 0.374 (0.374 
,0.375) 
0.578 (0.568, 
0.588) 
ADVANCE Overall 9.7 2.00 (2.53) 0.08 1.808 (1.805 
,1.811) 
0.666 (0.661, 
0.671) 
30-45 3.4 0.58 (0.45) 0.02 3.283 (3.277 
,3.289) 
0.628 (0.605, 
0.651) 
46-60 6.8 1.33 (0.96) 0.06 2.353 (2.350 
,2.356) 
0.595 (0.586, 
0.605) 
61-75 11.5 2.93 (2.09) 0.08 1.657 (1.655 
,1.660) 
0.594 (0.587, 
0.602) 
>75 21.0 6.27 (4.57) 0.15 0.973 (0.970 
,0.976) 
0.575 (0.565, 
0.585) 
CHS Overall 9.7 11.71 
(11.17) 
-0.02 0.631 (0.631 
,0.632) 
0.674 (0.669, 
0.679) 
30-45 3.4 4.58 (2.92) -0.02 0.760 (0.759 
,0.760) 
0.638 (0.615, 
0.661) 
46-60 6.8 8.68 (5.34) -0.02 0.742 (0.742 
,0.742) 
0.622 (0.613, 
0.632) 
61-75 11.5 16.1 (9.64) -0.05 0.546 (0.545 
,0.547) 
0.603 (0.596, 
0.611) 
>75 21.0 26.17 
(15.56) 
-0.05 0.398 (0.396 
,0.400) 
0.575 (0.565, 
0.585) 
Fremantle 
Diabetes 
Study 
Overall 9.7 5.24 (7.63) 0.05 0.738 (0.737 
,0.738) 
0.665 (0.660, 
0.670) 
30-45 3.4 1.2 (0.88) 0.02 2.025 (2.023 
,2.027) 
0.626 (0.603, 
0.648) 
46-60 6.8 3.23 (2.2) 0.04 1.157 (1.156 
,1.159) 
0.591 (0.582, 
0.600) 
61-75 11.5 8.49 (5.52) 0.03 0.736 (0.735 
,0.736) 
0.593 (0.585, 
0.600) 
>75 21.0 20.63 
(12.11) 
0.00 0.497 (0.496 
,0.497) 
0.580 (0.570, 
0.590) 
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NZ DCS Overall 9.7 16.17 
(10.87) 
-0.06 0.725 (0.725 
,0.725) 
0.670 (0.665, 
0.674) 
30-45 3.4 7.7 (2.9) -0.05 0.679 (0.676 
,0.683) 
0.645 (0.622, 
0.667) 
46-60 6.8 12.67 
(4.37) 
-0.06 0.740 (0.739 
,0.741) 
0.609 (0.599, 
0.618) 
61-75 11.5 20.23 
(6.39) 
-0.09 0.725 (0.725 
,0.726) 
0.599 (0.591, 
0.606) 
>75 21.0 30.45 
(8.42) 
-0.09 0.635 (0.633 
,0.638) 
0.573 (0.563, 
0.583) 
Swedish 
NDR 
Overall 9.7 8.26 (6.79) 0.02 0.955 (0.954 
,0.955) 
0.663 (0.658, 
0.668) 
30-45 3.4 3.67 (2.26) -0.01 0.871 (0.871 
,0.871) 
0.632 (0.609, 
0.654) 
46-60 6.8 6.44 (3.56) 0.01 0.869 (0.869 
,0.870) 
0.602 (0.592, 
0.611) 
61-75 11.5 10.54 
(5.62) 
0.00 0.727 (0.727 
,0.727) 
0.589 (0.582, 
0.596) 
>75 21.0 16.79 
(8.74) 
0.04 0.576 (0.575 
,0.576) 
0.566 (0.556, 
0.575) 
 
 
Figure Legends: 
Figure 1: Calibration plots for observed vs. predicted 5-year risk of CVD as estimated using 
QRISK2, ADVANCE, CHS, Fremantle Diabetes Study, New Zealand Diabetes Cohort Study 
and Swedish National Diabetes Register risk scores in people diagnosed with type 2 diabetes 
between 2004 and 2016 in Scotland† 
 
 
† Grey dashed line reflects perfect agreement between observed and predicted risk
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